Amylin-Based Pharmacotherapy – Past, Present & Future

Author(s): Jonathan D. Roth, Christine M. Mack, Christopher J. Soares, Soumitra S. Ghosh, David G. Parkes

Journal Name: Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization)
Formerly Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents

Volume 8 , Issue 4 , 2008


We briefly summarize evidence from non-clinical and clinical studies that amylin agonism has a physiological role in glucose and body weight regulation. Next, the amylin analog pramlintide is highlighted as part of an integrated neurohormonal therapeutic approach in both diabetes and weight management. Finally, attributes of, and analoging strategies to, the amylin molecule are discussed with the goal of improving targeted properties leading to the development of an optimized therapeutic candidate.

Keywords: Pharmacotherapy, clinical studies, amylin agonism, autoradiography, receptor, Glucoregulatory Control

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [317 - 324]
Pages: 8
DOI: 10.2174/187152208787169189
Price: $58

Article Metrics

PDF: 7